Randomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC)

被引：0
|
作者：
de Bono, J. [1 ,2 ]
Bracarda, S. [3 ,4 ]
Chi, K. [5 ]
Massard, C. [6 ]
Olmos Hidalgo, D. [7 ]
Sandhu, S. [8 ]
Sternberg, C. N. [9 ]
Gendreau, S. [10 ]
Xu, N. [11 ]
Baney, T. [12 ]
Maslyar, D. [13 ]
Sweeney, C. J. [14 ]
机构：
[1] Inst Canc Res, Div Clin Studies & Expt Med, London, England
[2] Royal Marsden Hosp, London, England
[3] ITT, Azienda USL Toscana Sud Est, Dept Oncol, Med Oncol, Arezzo, Italy
[4] Osped San Donato, Arezzo, Italy
[5] BC Canc Agcy, Clin Trials Unit, Vancouver, BC, Canada
[6] Inst Gustave Roussy, Early Drug Dev Dept, Villejuif, France
[7] Spanish Natl Canc Res Ctr, Prostate Canc Clin Res Unit, Madrid, Spain
[8] Peter MacCallum Canc Ctr, Dept Oncol, Melbourne, Vic, Australia
[9] San Camillo & Forlanini Hosp, Dept Oncol, Rome, Italy
[10] Genentech Inc, Late Stage Biomarker Dev, San Francisco, CA 94080 USA
[11] Genentech Inc, Biostat Oncol Solid Tumor, San Francisco, CA 94080 USA
[12] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
[13] Genentech Inc, Prod Dev Clin Oncol, San Francisco, CA 94080 USA
[14] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
834TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer
    George, Daniel J.
    Halabi, Susan
    Heath, Elisabeth I.
    Sartor, A. Oliver
    Sonpavde, Guru P.
    Das, Devika
    Bitting, Rhonda L.
    Berry, William
    Healy, Patrick
    Anand, Monika
    Winters, Carol
    Riggan, Colleen
    Kephart, Julie
    Wilder, Rhonda
    Shobe, Kellie
    Rasmussen, Julia
    Milowsky, Matthew I.
    Fleming, Mark T.
    Bearden, James
    Goodman, Michael
    Zhang, Tian
    Harrison, Michael R.
    McNamara, Megan
    Zhang, Dadong
    LaCroix, Bonnie L.
    Kittles, Rick A.
    Patierno, Brendon M.
    Sibley, Alexander B.
    Patierno, Steven R.
    Owzar, Kouros
    Hyslop, Terry
    Freedman, Jennifer A.
    Armstrong, Andrew J.
    CANCER, 2021, 127 (16) : 2954 - 2965
  • [2] Abiraterone plus prednisone alone or with dasatinib in chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC).
    Dorff, Tanya B.
    Groshen, Susan G.
    Quinn, David I.
    Goldkorn, Amir
    Martel, Cynthia L.
    Pinski, Jacek K.
    Kuhn, Pater
    Gross, Mitchell E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] A prospective trial of apalutamide and abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer
    George, Daniel J.
    Halabi, Susan
    Fleming, Mark T.
    Heath, Elisabeth I.
    Tutrone, Ronald F.
    Sutton, Linda
    Whang, Young E.
    Lewis, Brian E.
    Humeniuk, Michael Sandon
    Berry, William R.
    Harrison, Michael Roger
    Hurrelbrink, Julia
    Shobe, Kellie
    Rasmussen, Julia
    Anand, Monika
    Reyes-Martinez, Marco
    Howard, Lauren
    Patierno, Steven R.
    Freedman, Jennifer A.
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] SYNERGY: A randomized phase III study comparing firstline docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC).
    Chi, K. N.
    De Bono, J. S.
    Higano, C. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Small, Eric Jay
    Lance, Raymond S.
    Redfern, Charles H.
    Millard, Frederick E.
    Gardner, Thomas A.
    Karsh, Lawrence Ivan
    Dawson, Nancy Ann
    McCoy, Candice
    Stubbs, Andrew
    DeVries, Todd
    dela Rosa, Corazon P.
    Sheikh, Nadeem A.
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] PROpel: Efficacy of abiraterone plus olaparib vs. abiraterone plus placebo in the first-line treatment of patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) at baseline
    Clarke, N. W.
    Armstrong, A. J.
    Thiery-Vuillemin, A.
    Oya, M.
    Shore, N.
    Procopio, G.
    Guedes, J. D.
    Arslan, C.
    Mehra, N.
    Parnis, F.
    Brown, E.
    Schlurmann, F.
    Joung, J. Y.
    Sugimoto, M.
    Sartor, O.
    Poehlein, C.
    Barker, L.
    Degboe, A.
    Saad, F.
    EUROPEAN UROLOGY, 2023, 83
  • [7] Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC).
    Monk, Paul
    Liu, Glenn
    Stadler, Walter Michael
    Geyer, Susan Michelle
    Sexton, Jennifer L.
    Wright, John Joseph
    Villalona-Calero, Miguel Angel
    Wade, James Lloyd
    Szmulewitz, Russell Zelig
    Gupta, Shilpa
    Mortazavi, Amir
    Dreicer, Robert
    Pili, Roberto
    Cooney, Matthew M.
    Dawson, Nancy Ann
    George, Saby
    Garcia, Jorge A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [8] IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)
    de Bono, J. S.
    Bracarda, S.
    Sternberg, C. N.
    Chi, K. N.
    Olmos, D.
    Sandhu, S.
    Massard, C.
    Matsubara, N.
    Alekseev, B.
    Gafanov, R.
    Parnis, F.
    Buchschacher, G. L., Jr.
    Corrales, L.
    Borre, M.
    Vasconcelos Alves, G.
    Garcia, J.
    Harle-Yge, M-L.
    Chen, G.
    Wongchenko, M. J.
    Sweeney, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S1153 - S1154
  • [9] Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer
    Heath, Elisabeth
    Heilbrun, Lance
    Mannuel, Heather
    Liu, Glenn
    Lara, Primo
    Monk, J. Paul
    Flaig, Thomas
    Zurita, Amado
    Mack, Philip
    Vaishampayan, Ulka
    Stella, Philip
    Smith, Daryn
    Bolton, Susan
    Hussain, Arif
    Al-Janadi, Anas
    Silbiger, Daniel
    Usman, Muhammad
    Ivy, S. Percy
    ONCOLOGIST, 2019, 24 (09): : 1149 - +
  • [10] Assessment of quality of life (QOL), cognitive function and depression in a randomized phase II study of abiraterone acetate (ABI) plus prednisone (P) vs enzalutamide (ENZA) for metastatic castrate-resistant prostate cancer (mCRPC).
    Khalaf, Daniel
    Sunderland, Katherine
    Eigl, Bernhard J.
    Finch, Daygen L.
    Oja, Conrad D.
    Vergidis, Joanna
    Parimi, Sunil
    Zulfiqar, Muhammad
    Gleave, Martin
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345